Cancer-fighting T cells burn out. Scientists may have found a fix

These cells continued to proliferate and secrete cytokines even after repeated exposure to cancer cells

Researchers at Memorial Sloan Kettering Cancer Center have identified a potential method to prevent tumor-fighting T cells from becoming exhausted during immunotherapy. The discovery, reported on October 5, 2026, could extend the effectiveness of cancer treatments that rely on the body’s immune system. By targeting a specific molecular pathway, scientists aim to keep T cells active longer against tumors. T cell exhaustion is a major obstacle in immunotherapy, where prolonged exposure to cancer cells causes these immune cells to lose their ability to attack. The research team found that blocking a protein called TOX, which drives exhaustion, helped maintain T cell function in preclinical models. This approach did not cause harmful overactivation, suggesting a balanced way to sustain immune response without triggering autoimmunity. How TOX Inhibition Preserves T Cell Function In laboratory experiments, T cells engineered to resist TOX activity showed improved persistence and tumor-killing capacity.

These cells continued to proliferate and secrete cytokines even after repeated exposure to cancer cells. The effect was observed across multiple cancer types, including melanoma and lung carcinoma models. Researchers noted that the modified T cells retained a stem-like memory state, which is associated with long-term immunity. Can This Approach Work in Human Patients? While the results are promising, the team cautions that mouse models do not always predict human outcomes. Clinical trials would be needed to test safety and efficacy in people. The next step involves developing drugs that can inhibit TOX without damaging healthy tissues. If successful, such therapies could be combined with existing checkpoint inhibitors to boost remission rates. Frequently Asked Questions What causes T cells to become exhausted in cancer? Continuous stimulation by tumor antigens leads to epigenetic changes that suppress T cell function over time, reducing their ability to fight cancer.

Is targeting TOX safe for patients? Early data suggest it avoids overactivation risks, but human trials are required to confirm safety and long-term effects. Could this help treat cancers resistant to current immunotherapy? Yes, by reversing exhaustion, this strategy may restore responsiveness in tumors that no longer respond to checkpoint blockade alone.